Close Menu

Vela Diagnostics

The partners will develop a multiplexed nucleic acid-based assay to detect carbapenem-resistant Enterobacteriaceae from whole blood samples.

The molecular diagnostics firm also received FDA clearance for a strep test and began clinical trials for an E. coli assay in the quarter.

The Group B Strep test is the second test on the firm's menu granted clearance, and is intended for screening pregnant women. 

The firm, which went public in October, made a public offering of more than 2.5 million units at $8.80 per unit. 

The company is offering about 2.7 million units consisting of preferred stock and warrants at $8.80 per unit. 

The increase in C. diff sales resulted from an increase in the number of Great Basin's customers, it said. 

The company filed a prospectus to offer units comprising its Series E convertible preferred stock and Series C warrants.

The Salt Lake City-based MDx firm has initiated a clinical trial for its sample-to-result Staph identification/resistance test.

NEW YORK (GenomeWeb News) – Since its founding in 2005, molecular diagnostics firm Great Basin has raised $36 million in private financing, including about $9.6 million in a Series B round completed


Researchers have sequenced the genome of the depth-dwelling giant squid.

Prosecutors have charged a former Drexel University professor with theft for allegedly spending federal grant money on adult entertainment and other unrelated expenses, according to the Philadelphia Inquirer.


Chris Collins, a former US representative, has been sentenced to more than two years in prison in an insider trading case involving an Australian biotechnology firm, the New York Times reports.

In PNAS this week: Trypanosoma brucei transcripts, estimate of people at risk of inherited retinal disease, and more.